California, New Hampshire, Pennsylvania and South Carolina ended Medicaid weight-management GLP-1 coverage on 1 January 2026. The authors used State Drug Utilization Data from 2024 Q1 to 2026 Q1, classifying products by FDA-approved indication. In the withdrawing states, prescriptions fell 85% between 2025 Q3 and 2026 Q1, from 1.06 to 0.16 per 100 enrollee-months. Six states that kept coverage went from 0.90 to 0.82 (difference-in-differences -0.67; 95% CI -1.21 to -0.18). GLP-1s labelled for other indications did not rise against 33 never-covering states (-0.03; 95% CI -0.29 to 0.23). The analysis covers only the first quarter after coverage ended.
Why it is interesting: These four states held 60.5% of national Medicaid weight-management GLP-1 prescriptions before coverage ended. Within one quarter their dispensing fell 85%, and dispensing of diabetes-labelled products did not rise.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.